[PRESS RELEASE]

MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.

Notice of Participation in Tokuyama Group

Tokyo, Japan – October 1, 2025 - Medical & Biological Laboratories Co., Ltd. (CEO: Hiroki Ito; hereinafter “MBL”) announces that MBL will join the group of Tokuyama Corporation (President: Hiroshi Yokota; hereinafter "Tokuyama”).

“Notice on the Transfer of In Vitro Diagnostic Business and In Vitro Diagnostic Materials Business - Including Medical & Biological Laboratories Co., Ltd. and JSR Life Sciences Corporation” was announced on April 22, 2025.

On October 1, 2025, Tokuyama completed the procedures to acquire all shares of the successor company in an absorption-type split. As a result, MBL has become part of Tokuyama Group.

Contact:
Medical & Biological Laboratories Co., Ltd.
General Affairs Department
Head Quarter: SUMITOMO FUDOSAN SHIBADAIMON NICHOME BLDG. 2-11-8 Shibadaimon, Minato-ku, Tokyo 105-0012 Japan
E-mail: https://www.mblbio.com/e/contact/general.html

About Medical & Biological Laboratories Co., Ltd.:

Medical & Biological Laboratories (MBL) was established in 1969 as the first antibody manufacturer in Japan, and researches, develops, manufactures, and sells reagents of in vitro diagnostics (IVD) and reagents for basic research. It has now expanded its business not only to the immunological field but also to the field of genetic diagnosis.

In the IVD business, we develop and sell IVD reagents for autoimmune diseases, cancer, infectious diseases, etc. Particularly in the field of autoantibody diagnosis, we are expanding our product lineup as a top manufacturer in Japan and contributing to medical care in this field where there are many intractable diseases. In the field of oncology, we are contributing to personalized medicine by developing companion diagnostics that predict the effects of drugs.

https://www.mblbio.com/e/

About Tokuyama Corporation:

Since founding in 1918, Tokuyama has worked to accumulate technologies and create new products by developing our inorganic chemicals business, while, from the 1970s, we began addressing social issues by expanding the scope of businesses, mainly in organic and polymer chemistry.

Under its Medium-Term Management Plan 2025, Tokuyama has identified the “Electronics,” “Healthcare,” and “Environment” fields as growth businesses. As a part of efforts to transform our business portfolio, our plan is to increase the proportion of consolidated sales generated from growth businesses to more than 60% by FY2030. Taking the aforementioned into consideration, our intention is to position the newly acquired IVD businesses at the heart of our healthcare domain.

https://www.tokuyama.co.jp/eng/